ASU,
By the looks of it you have adopted this board by default. PM posting has certainly dried up.
I think this forum does need an ample supply of scientific rhetoric however, so I would hate to see certain individuals go....It is what brought me to this board in the first place and what did cause me to create such a high stake in COR. In hind sight I wish maybe I had never found it but here we are.
The powers that be will always be criticized. Certain indiviuals should understand that. So when you stand up to the podium expect the most difficult questions and harshest judgment. I really am having a hard time wondering why there is so much sensitivity here. I just lost a $400K new house, you even more, if that does not warrant a bit of harsh scepticism then what should?
From a business standpoint I think the pipe was a mistake even now. When things did look brighter for COR and there was apparent BP interest, that is when financing should have been secured or a deal made.
In the wake of the most recent financing, Stoll should have aquired enough cash to get us further down the road. If CX701 is our next great hope then he cetainly should have funds available to advance it in house.
I do think, again from a business stand, that the hiring of Tran is a positive move. He has street cred and experience with successful teams moving compounds forward. I guess I am not quite sure as to why Stoll did not bring someone such as Tran in sooner to offer an experienced point of view to the FDA process.
Lastly, would there not have been as much BP interest for just AD? If the psych division, as of late, seems so apprehensive to approve new drugs then why go there? Was there not an opportunity to market CX717 for just AD? Anybody? Anybody out there?
